Many companies are attempting to reduce the GI bleeding, ulcers and perforations caused by administration of NSAIDS (e.g., ibuprofen, naproxen, aspirin). Since Vioxx was removed from the market (and it was a safer NSAID with respect to GI), there has been an surge of NSAID activity around these existing actives. We understand that the FDA’s [...]
Search
About
You are currently browsing the Drug Kennel weblog archives for the day Sunday, June 15th, 2008.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Latest
- Failed 505(b)(2)?: Vivus’ Qnexa
- Will We Have Generic User Fees? Public Meeting To Be Held.
- Lannett’s Morphine Sulfate Oral Solution: 505(b)(2) or 505j?
- Generic Lovenox – 505j or 505(b)(2)
- New User Fees for 2011
- Still submitting paper ANDA applications?
- What should a license cost?
- Avandia: Who Won?
- Advisory Committee Meeting: Rosiglitazone
- The skinny on a potential new treatment of obesity
Improved Bioavailability Allows Return to Sleep and wake-up fresh
Published June 15th, 2008 in News Commentary. 0 CommentsTranscept Pharmaceuticals presented a poster June 11, 2008 at the Associated Professional Sleep Societies (APSS) regarding their investigational product, a low-dose, sublingual version of zolpiderm (RLD: Sanofi-Aventis’ Ambien®). In the press release announcing this poster, Transcept indicated that their new formulation, Intermezzo®, “delivered overall bioavailability that was significantly greater than that produced by a swallowed Ambien® tablet containing [...]